Does Substance P cause pain?

Substance P doesn't directly cause pain but amplifies pain signals in the spinal cord and contributes to central sensitisation. It also triggers neurogenic inflammation in peripheral tissues, which can enhance pain perception.

Can blocking Substance P treat chronic pain?

Despite strong preclinical evidence, NK1R antagonists showed disappointing results in human pain trials. Pain processing involves many redundant pathways, and blocking Substance P alone appears insufficient for clinical analgesia.

What is the connection between Substance P and stress?

Substance P levels increase during stress, and it's involved in the stress-anxiety-pain axis. NK1R antagonists have shown anxiolytic properties in some studies, suggesting Substance P contributes to stress-related psychiatric symptoms.

How does aprepitant (Emend) relate to Substance P?

Aprepitant is an NK1R antagonist—it blocks the receptor where Substance P acts. By blocking Substance P signaling in the vomiting centre, it effectively prevents chemotherapy-induced nausea. It is an approved prescription medication.

Fact-checked by the Peptide Authority Editorial Board · Last reviewed: 8 March 2026

Share:X Post LinkedIn

Neuropeptides•Updated 2026-03-08•5 min read

What Is Substance P? Benefits, Research & Safety

A key neuropeptide involved in pain transmission, inflammation, and mood regulation, and the target of the first neuropeptide receptor antagonist drug.

Share:X Post LinkedIn

Also known as:

Neurokinin A precursor

Tachykinin

AStrong human evidenceUK: Sold as 'research only' (UK)WADA: Sport status unclear

UK summary: Endogenous neuropeptide involved in pain and neurogenic inflammation. Not a medicine; NK1-receptor antagonists (e.g. aprepitant) are licensed UK antiemetics that work against Substance P signalling.

Quick Facts

Overview

Substance P is an 11-amino acid neuropeptide belonging to the tachykinin peptide family. It is one of the most extensively studied neuropeptides, with critical roles in pain transmission, neurogenic inflammation, mood regulation, and gut function. Substance P is widely distributed throughout the nervous system, particularly in sensory neurons (C-fibres and Aδ-fibres), the spinal cord, and brain regions involved in pain processing, emotional regulation, and the vomiting reflex. It acts primarily through the neurokinin-1 receptor (NK1R). In pain processing, Substance P is released from primary afferent nerve terminals in the spinal cord dorsal horn, where it amplifies pain signals and contributes to central sensitisation. In peripheral tissues, it triggers neurogenic inflammation—vasodilation, plasma extravasation, and immune cell recruitment. The development of NK1R antagonists represented a major advance in understanding Substance P's functions. While initial trials for pain relief were disappointing, the NK1R antagonist aprepitant proved highly effective as an anti-emetic (preventing chemotherapy-induced nausea and vomiting), leading to its approval as Emend. Substance P and NK1R have also been implicated in mood disorders, with research suggesting that NK1R antagonists may have antidepressant and anxiolytic properties, though clinical trial results have been mixed.

Evidence standards summary

Substance P — evidence and risk at a glance

Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.

01Evidence snapshot

AStrong human evidenceOverall grade against our evidence grading methodology.

Endogenous neuropeptide involved in pain and neurogenic inflammation. Not a medicine; NK1-receptor antagonists (e.g. aprepitant) are licensed UK antiemetics that work against Substance P signalling.

02Human evidence grade

AStrong human evidenceStrength of evidence from published human trials.

03Preclinical evidence grade

AStrong human evidenceAnimal-model and in-vitro evidence quality.

04Regulatory status

UK: Substance P is an endogenous peptide used as a research tool. NK1R antagonists (aprepitant) are licensed medications.
EU: Same—Substance P is a research tool; NK1R antagonists are approved anti-emetics.
Notes: Substance P itself is not a therapeutic but is crucial for understanding pain and inflammation. NK1R antagonists represent an important therapeutic class. Research continues into broader applications of NK1R blockade.

05Approved medical uses

None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)

06Unapproved / promotional claims

Substance P supplements treat chronic pain.
Oral 'pain peptide' lifts pain naturally.

07Common internet claims

Marketed as a wellness supplement on the 'nature's pain pathway' story.

08Claim vs evidence

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Substance P supplements affect pain perception”	E	No	High	Substance P cannot be taken orally; pain treatment requires licensed medicines and clinical assessment.

09Safety uncertainty score

Moderate

Safety profile partly characterised; some signals from observational or preclinical data.

10Known adverse signals

Oral peptide is degraded and biologically inert.
Injectable use is research-stage and not safety-tested.

11Drug-interaction uncertainty

Moderate

Some interaction data published; check with a prescriber for your specific medicines.

12Anti-doping status

WADA: Sport status unclearWADA strict-liability framing applies.

13UK legal position

UK: Sold as 'research only' (UK)

Substance P is an endogenous peptide used as a research tool. NK1R antagonists (aprepitant) are licensed medications.

14EU legal position

Same—Substance P is a research tool; NK1R antagonists are approved anti-emetics.

15What this page cannot tell you

What 'Substance P supplements' actually contain.
Whether they produce any measurable physiological effect.

16Last reviewed

Last reviewed: 8 March 2026

Next review due: 8 March 2027

Spotted an error or something out of date? Send a correction.

17Citation quality score

AStrong human evidenceQuality of the sources we cite, graded against the evidence grading methodology.

18Research gaps

NK1-receptor antagonist drug development is the practical Substance P pathway pharmacology; not a supplement route.

19Safer alternatives / established care pathways

NHS pain-clinic referral for chronic pain.
Licensed analgesics per NICE NG193 / cause-specific guidelines.
CBT for chronic-pain coping via NHS Talking Therapies.

20Doctor discussion prompts

Questions to ask a qualified clinician

These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

What evidence-based pain management options are appropriate for my situation?

Discovery & History

Substance P was one of the first neuropeptides discovered. Ulf von Euler and John Gaddum identified it in 1931 in equine brain and intestinal extracts as a substance that caused smooth muscle contraction and vasodilation. They named it "Substance P" with "P" standing for "preparation" or "powder." The complete amino acid sequence was determined by Susan Leeman and colleagues in 1971, revealing it to be an 11-amino acid peptide (Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2). In the 1970s-1980s, immunohistochemical studies revealed Substance P's widespread distribution in the nervous system. Its role in pain transmission was established through studies showing its presence in sensory neurons and spinal cord. The cloning of the NK1 receptor in the early 1990s enabled development of selective antagonists. Merck developed aprepitant (MK-869), initially as an analgesic/antidepressant. While analgesic trials were unsuccessful, its anti-emetic efficacy was remarkable, leading to FDA approval as Emend in 2003. Research continues into NK1R antagonists for depression, anxiety, and other conditions.

Mechanism of Action

Substance P signals primarily through the NK1 receptor: **NK1 Receptor Activation** Primary signaling pathway: - Binds NK1R (a G-protein coupled receptor) with highest affinity - Activates Gq/11 signaling cascade - Increases intracellular calcium via IP3 - Activates protein kinase C and downstream effectors **Pain Transmission** Role in nociceptive processing: - Released from C-fibre terminals in spinal cord dorsal horn - Enhances NMDA receptor activation (central sensitisation) - Amplifies pain signals through "wind-up" phenomenon - Contributes to chronic pain states through neuroplastic changes **Neurogenic Inflammation** Peripheral inflammatory effects: - Vasodilation via endothelial NK1R activation - Plasma extravasation (increased vascular permeability) - Mast cell degranulation and histamine release - Immune cell recruitment and activation - Contributes to conditions like migraine, arthritis, and IBD **Emetic Pathway** Role in nausea and vomiting: - Acts on NK1R in the nucleus tractus solitarius and area postrema - Key mediator of chemotherapy-induced delayed emesis - Target for anti-emetic drugs (aprepitant, fosaprepitant)

Researched Benefits

Based on preclinical and clinical research findings:

1
Understanding pain transmission mechanisms
2
NK1R antagonists approved as anti-emetics (aprepitant/Emend)
3
Potential target for chronic pain therapeutics
4
Research into antidepressant effects of NK1R blockade
5
Biomarker for neuroinflammatory conditions
6
Role in wound healing and tissue repair
7
Understanding neurogenic inflammation

Claim vs Evidence

How popular claims about Substance P stack up against the current research, graded using our public evidence grading methodology.

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Substance P supplements affect pain perception”	E	No	High	Substance P cannot be taken orally; pain treatment requires licensed medicines and clinical assessment.

Theoretical Dosing & Protocols

⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.

Theoretical Dosage	Substance P itself is not administered therapeutically
Frequency	N/A
Duration	N/A
Notes	Substance P is an endogenous neuropeptide. Clinical interest focuses on NK1R antagonists that block Substance P's effects. Aprepitant (Emend) is the primary approved NK1R antagonist, used for prevention of chemotherapy-induced nausea.

Administration Routes

Routes studied in research settings (educational only):

Not administered therapeutically (endogenous neuropeptide)
Used in research for pain/inflammation studies

Half-Life	Stability
Very short (minutes) due to rapid enzymatic degradation by neutral endopeptidase	Rapidly degraded in vivo; research preparations require protease inhibitors

Safety Profile & Known Risks

Commonly Reported Side Effects

Not administered therapeutically

Rare Risks & Concerns

Elevated Substance P levels associated with chronic pain and inflammation
Excessive neurogenic inflammation
Contribution to inflammatory disease pathology

Contraindications

Not a therapeutic agent

UK & EU Regulatory Context

🇬🇧 United Kingdom

Substance P is an endogenous peptide used as a research tool. NK1R antagonists (aprepitant) are licensed medications.

🇪🇺 European Union

Same—Substance P is a research tool; NK1R antagonists are approved anti-emetics.

Substance P itself is not a therapeutic but is crucial for understanding pain and inflammation. NK1R antagonists represent an important therapeutic class. Research continues into broader applications of NK1R blockade.

Clinical Studies Summary

Neurophysiological Effects of Dry Needling: A Systematic Review and Meta-analysis.

The application of dry needling can induce significant changes in pain-related biomarker levels in animal and human studies, providing insights into its underlying mechanisms of action and potential clinical effects.

Arch Phys Med Rehabil. 2026View on PubMed

Inflammatory Biomarkers in Irreversible Pulpitis and Pulp Necrosis: A Systematic Review and Meta-Analysis.

Both SIP and AIP exhibit pro-inflammatory profiles, with TNF-α elevated regardless of symptoms. Molecular biomarkers may better reflect pulp status than clinical signs.

Int Dent J. 2026View on PubMed

Effects of Auricular Stimulation on Inflammatory Parameters: Results of a Systematic Review and Meta-Analysis of Randomized Controlled Trials.

The influence of inflammatory cytokines seems to be mediated by AS. More research is needed to investigate the effects of AS on the immunologic system in addition to its clinical significance in high-quality RCT.

Neuromodulation. 2025View on PubMed

Neurochemical Alterations in Aggression: A Meta-Analysis.

The findings for the other neurochemicals all did not reach statistical significance. These findings suggest that reduced prefrontal NAA levels may serve as a neurobiological correlate of aggressive behaviours, with implications for developing assessment tools and targeted interventions.

Psychiatry Res. 2025View on PubMed

Association between brain-gut peptides and depression: A systematic review and meta-analysis.

The findings suggest that increased serum concentrations of SP, CCK, and ghrelin are associated with depressive disorders, highlighting their potential as important biomarkers for the detection of depression. In contrast, the role of LEP in depression remains inconclusive and warrants further investigation.

Psychoneuroendocrinology. 2025View on PubMed

Systemic neurokinin-1 receptor antagonists mitigate chronic pruritus: A systematic review and meta-analysis.

Our study suggests that systemic NK1R antagonists, particularly serlopitant and aprepitant, hold modest therapeutic effect for treating chronic pruritus, particularly in patients with nonmalignant dermatological conditions. Thus, clinicians can consider NK1R antagonists to effectively interrupt itch signaling in patients with chronic pruritus.

J Eur Acad Dermatol Venereol. 2025View on PubMed

Registered Trials & Regulatory Status

Registered trials

Currently recruiting

Furthest phase

Phase 4

Approved product

10 of 15 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.

Postoperative Pain and Substance P Levels After Bioceramic vs Calcium Hydroxide Intracanal Medicaments in Symptomatic Apical Periodontitis

Status: Not Yet Recruiting · 28 participants · Future University in Egypt

Conditions: Symptomatic Apical Periodontitis

No results postedNCT07585721

Substance P-Induced Migraine Attacks Without Aura

Status: Recruiting · 21 participants · Danish Headache Center

Conditions: Migraine

No results postedNCT06959004

Effects of Substance P on Headache Induction in Healthy Individuals

Status: Not Yet Recruiting · 21 participants · Danish Headache Center

Conditions: Healthy Volunteers Only

No results postedNCT06632080

EFFECT OF A SUBSTANCE P ANTAGONIST ON THE SECRETION OF ALDOSTERONE IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA SYNDROME AND ARTERIAL HYPERTENSION

PHASE2

Status: Recruiting · 24 participants · University Hospital, Rouen

Conditions: Apnea, Obstructive

No results postedNCT06462287

Evaluation of the Levels of Calcitonin Gene-related Peptide and Substance P

N/A

Status: Recruiting · 51 participants · Melike Cengiz

Conditions: Meningitis, Diagnosis, Prognosis

No results postedNCT06510751

The Effect of Different Intraradicular Cryotherapy on Post-operative Pain and the Level of Substance P

Status: Completed · 135 participants · Ain Shams University

Conditions: Post Operative Pain, Inflammation

No results postedNCT06106386

Substance P Challenge in Healthy Participants

Status: Completed · 32 participants · GlaxoSmithKline

Conditions: Skin Diseases

Results postedNCT04676763

Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1

PHASE4

Status: Terminated · 4 participants · Vanderbilt University Medical Center

Conditions: Hypertension

Results postedNCT03738878

Substance P as a Biomarker to Evaluate the Reduction of Multiple Immunization Pain

Status: Completed · 132 participants · Jordan University of Science and Technology

Conditions: Immunisation Anxiety Related Reaction, Pain, Acute

No results postedNCT04103801

The Effect of Beta-blockers in Substance P Levels and the Swallowing Function

N/A

Status: Unknown · 60 participants · Hospital de Mataró

Conditions: Beta Blockers, Swallowing Disorder, Substance P

No results postedNCT03306134

Regional Anaesthesia and Substance P in Head and Neck Cancer

Status: Suspended · 40 participants · Charite University, Berlin, Germany

Conditions: Head and Neck Cancer

No results postedNCT03081897

Neuropeptide Therapy of Recent Onset Type 1 Diabetes

PHASE1

Status: Unknown · 12 participants · Vanilloid Genetics Inc.

Conditions: Diabetes Mellitus, Type 1

No results postedNCT02820558

Adverse event reports (FDA FAERS)

Not applicable: no licensed product contains this peptide, so it is not reported through FAERS. This is an absence of surveillance, not evidence of safety.

Source: ClinicalTrials.gov and openFDA. Updated automatically.

Looking for Substance P?

Source research-grade Substance P from a trusted UK supplier — third-party tested with certificate of analysis.

View at Supplier

Frequently Asked Questions

Questions to ask a qualified clinician about Substance P